How does Upadacitinib treat psoriasis?

Psoriatic arthritis is a chronic systemic inflammatory disease with a variable clinical course, often associated with joint inflammation and cutaneous psoriasis. Two studies of patients with previously treated active psoriatic arthritis showed that upadacitinib, alone or in combination with methotrexate, was more effective than adalimumab (another drug used for psoriatic arthritis) or placebo in reducing disease symptoms. After 12 weeks of treatment, 57-71% of patients taking upapatinib experienced symptom relief. Another analysis showed that upadacitinib plus methotrexate had similar efficacy to upadacitinib monotherapy, both in biologic-naive patients and in patients previously treated with biologics.